Bastos 2019 Clin Mol Hepatol: Difference between revisions
From Bioblast
(Created page with "{{Publication |title=Bastos KLM, Quaio CR, Lima FR, Araújo IM, Araújo CAT, Piazzon FB, Silva IDCG, Benevides GN, Tannuri AC, Tannuri U, Azevedo RA, Kim CA (2019) Biochemical...") |
No edit summary |
||
| Line 6: | Line 6: | ||
|journal=Clin Mol Hepatol | |journal=Clin Mol Hepatol | ||
}} | }} | ||
== Cited by == | |||
{{Template:Cited by Silva 2021 MitoFit Etomoxir}} | |||
{{Labeling | {{Labeling | ||
|additional=MitoFit 2021 Etomoxir | |additional=MitoFit 2021 Etomoxir | ||
}} | }} | ||
Latest revision as of 18:17, 31 May 2022
| Bastos KLM, Quaio CR, Lima FR, Araújo IM, Araújo CAT, Piazzon FB, Silva IDCG, Benevides GN, Tannuri AC, Tannuri U, Azevedo RA, Kim CA (2019) Biochemical profile in an infant with neonatal hemochromatosis shows evidence of impairment of mitochondrial long-chain fatty acid oxidation. Clin Mol Hepatol 25:86-91. |
Bastos KLM, Quaio CR, Lima FR, Araújo IM, Araújo CAT, Piazzon FB, Silva IDCG, Benevides GN, Tannuri AC, Tannuri U, Azevedo RA, Kim CA (2019) Clin Mol Hepatol
Abstract:
Cited by
- Silva et al (2021) Off-target effect of etomoxir on mitochondrial Complex I. MitoFit Preprints 2021. (in preparation)
Labels:
MitoFit 2021 Etomoxir
